Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $30.20.

Several research analysts recently issued reports on the stock. Wells Fargo & Company set a $23.00 price target on shares of Arcus Biosciences and gave the stock an “equal weight” rating in a research note on Thursday, February 12th. Citigroup upped their price objective on shares of Arcus Biosciences from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday. UBS Group reaffirmed a “buy” rating on shares of Arcus Biosciences in a research note on Monday, December 15th. HC Wainwright reiterated a “buy” rating and set a $32.00 target price on shares of Arcus Biosciences in a report on Monday, March 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Wednesday, January 21st.

Arcus Biosciences Stock Down 0.4%

Shares of NYSE RCUS traded down $0.09 during mid-day trading on Friday, hitting $22.12. 653,865 shares of the stock traded hands, compared to its average volume of 1,181,735. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -6.70 and a beta of 0.85. The stock has a fifty day moving average price of $21.52 and a 200-day moving average price of $18.88. Arcus Biosciences has a 52 week low of $6.50 and a 52 week high of $26.40. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.36 and a current ratio of 4.36.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.22. Arcus Biosciences had a negative return on equity of 65.77% and a negative net margin of 142.91%.The business had revenue of $33.00 million during the quarter, compared to the consensus estimate of $24.94 million. During the same quarter in the prior year, the company earned ($1.03) earnings per share. The firm’s quarterly revenue was down 8.3% compared to the same quarter last year. Research analysts anticipate that Arcus Biosciences will post -3.15 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Alexander Azoy sold 4,343 shares of Arcus Biosciences stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $22.25, for a total value of $96,631.75. Following the completion of the transaction, the chief accounting officer owned 18,531 shares of the company’s stock, valued at $412,314.75. The trade was a 18.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert C. Goeltz II sold 6,552 shares of the company’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $23.38, for a total transaction of $153,185.76. Following the completion of the transaction, the chief financial officer owned 67,924 shares in the company, valued at approximately $1,588,063.12. The trade was a 8.80% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 180,990 shares of company stock valued at $3,974,764. Company insiders own 9.60% of the company’s stock.

Institutional Trading of Arcus Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of RCUS. GAMMA Investing LLC lifted its stake in shares of Arcus Biosciences by 59.1% in the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after buying an additional 1,021 shares in the last quarter. Hantz Financial Services Inc. increased its position in shares of Arcus Biosciences by 121.9% during the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after acquiring an additional 881 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in Arcus Biosciences by 13,547.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after acquiring an additional 2,845 shares during the last quarter. T. Rowe Price Investment Management Inc. bought a new position in Arcus Biosciences in the 4th quarter valued at approximately $39,000. Finally, CWM LLC lifted its position in Arcus Biosciences by 233.6% in the 2nd quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after acquiring an additional 3,810 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.